|
Celiac Disease
|
0.300 |
Biomarker
|
disease |
CTD_human |
Celiac disease biomarkers identified by transcriptome analysis of small intestinal biopsies.
|
30097691 |
2018 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Acyl-coenzyme A:cholesterol acyltransferase-2 (ACAT-2) is responsible for elevated intestinal ACAT activity in diabetic rats.
|
15242859 |
2004 |
|
Kidney Failure, Chronic
|
0.200 |
Biomarker
|
disease |
RGD |
The CRF animals showed a significant reduction in creatinine clearance, marked hypertriglyceridemia, modest hypercholesterolemia, and significant upregulation of hepatic tissue ACAT-2 protein and mRNA abundance.
|
12217884 |
2002 |
|
Nephrotic Syndrome
|
0.200 |
Biomarker
|
group |
RGD |
Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.
|
11967026 |
2002 |
|
Chronic kidney disease stage 5
|
0.200 |
Biomarker
|
disease |
RGD |
Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure.
|
12217884 |
2002 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of the cholesterol esterifying enzyme acyl-Coenzyme A: cholesterol acyltransferase 2 (ACAT2, encoded by Soat2) protects mice from atherosclerosis, diet-induced hypercholesterolemia, and hepatic steatosis when fed high-cholesterol diet.
|
30630736 |
2019 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of the cholesterol esterifying enzyme acyl-Coenzyme A: cholesterol acyltransferase 2 (ACAT2, encoded by Soat2) protects mice from atherosclerosis, diet-induced hypercholesterolemia, and hepatic steatosis when fed high-cholesterol diet.
|
30630736 |
2019 |
|
Hypercholesterolemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The ACAT-2 and CYP7A1 mRNA expression were significantly decreased in HC diet supplemented with STG, while the mRNA levels of LDLR were markedly increased.
|
30937311 |
2019 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Rs28765985 of ACAT-2 gene are associated with CAD in Uygur subjects.
|
30696703 |
2019 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here we aimed to investigate whether depletion of Soat2 per se can reduce hepatic steatosis, also in the presence of very low levels of cholesterol in the diet, and the underlying mechanisms.
|
30630736 |
2019 |
|
Wolman Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, these data imply that SOAT2 inhibition, if applied concurrently with enzyme replacement therapy for LAL deficiency, may blunt the re-esterification of newly released unesterified cholesterol thereby improving clinical outcomes.
|
29246491 |
2018 |
|
Dyslipidemias
|
0.020 |
Biomarker
|
group |
BEFREE |
These new analogues are the most potent and selective SOAT2 inhibitors to be used as synthetic compounds and attractive seed compounds for the development of drug for dyslipidemia, including atherosclerotic disease and steatosis.
|
29323466 |
2018 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These new analogues are the most potent and selective SOAT2 inhibitors to be used as synthetic compounds and attractive seed compounds for the development of drug for dyslipidemia, including atherosclerotic disease and steatosis.
|
29323466 |
2018 |
|
Wolman Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.
|
25450374 |
2014 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Hypercholesterolemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To explore the possible impact of ACAT2 gene variants on CAD susceptibility and plasma lipid levels, three polymorphisms, 41A>G (Glu>Gly), 734C>T (Thr>Ile), and IVS4-57_58 ins48 bp (D/I), were genotyped in 809 CAD patients (CAD+) and 1,304 controls (CAD-) from three distinct Singaporean ethnic groups (1,228 Chinese, 367 Malays and 518 Indians).
|
16195894 |
2005 |
|
Dyslipidemias
|
0.020 |
Biomarker
|
group |
BEFREE |
To investigate the relationship between ACAT-2 and dyslipidemia, we determined the structure of the human ACAT-2 gene and then studied the relationship between mutations of the ACAT-2 gene and dyslipidemia.
|
11325614 |
2001 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we aimed to investigate whether depletion of Soat2 per se can reduce hepatic steatosis, also in the presence of very low levels of cholesterol in the diet, and the underlying mechanisms.
|
30630736 |
2019 |
|
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CKD also resulted in increased enzymatic activity of HMG-CoA reductase and ACAT2 together with decreased enzyme activity of lipase and LCAT.
|
31828139 |
2019 |
|
Liver diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The existence of a new class of potent and selective SOAT2 inhibitors provides an opportunity for exploring if suppression of this enzyme could potentially become an adjunctive therapy for liver disease in NPC1 deficiency.
|
29878847 |
2018 |
|
Liver mass
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In the chow-fed mice, NPC1:SOAT2 double knockouts, compared with their littermates lacking only NPC1, had 20% less liver mass, 28% lower hepatic UC concentrations, and plasma alanine aminotransferase and aspartate aminotransferase activities that were decreased by 48% and 36%, respectively. mRNA expression levels for several markers of inflammation were all significantly lower in the NPC1 mutants lacking SOAT2.
|
29878847 |
2018 |
|
Acid cholesteryl ester hydrolase deficiency, type 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these data imply that SOAT2 inhibition, if applied concurrently with enzyme replacement therapy for LAL deficiency, may blunt the re-esterification of newly released unesterified cholesterol thereby improving clinical outcomes.
|
29246491 |
2018 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In mouse models, previous work has demonstrated that either antisense oligonucleotide (ASO) or small molecule inhibitors of SOAT2 can effectively reduce CVD progression, and even promote regression of established CVD.
|
26729489 |
2016 |